I think you are wise Dr. with your remarks. Volume is up, but not in a major way. The current valuation imo is very skewed to the low end and with such an ultra low float, a meaningful buyer coming in can cause some meaningful movment in stock. With cash runway out to 2012 and a quality adjunct therapy moving into two Phase IIIs...along with another compound (i.e. 427) looking promising as it workds thru the develoment gauntlet, its a function of time before a more reasonable valuation emerges.
I have said before and still beleive that buys between $12-15 a share offers an investor a low risk way to enjoy very robust upside as times rolls on.
Soon enough we will see if this upside will find traction and if a bottom will be defined. One never knows until they look into the rear view mirror.